GVHD-associated chronic kidney disease after allogeneic haematopoietic cell transplantation

I Sakellari, A Barbouti, G Bamichas, D Mallouri… - Bone marrow …, 2013 - nature.com
I Sakellari, A Barbouti, G Bamichas, D Mallouri, P Kaloyannidis, S Fragidis, I Batsis…
Bone marrow transplantation, 2013nature.com
Chronic kidney disease (CKD) has been related to allogeneic haematopoietic cell
transplantation (HCT) as a late effect caused by a variety of factors. We retrospectively
evaluated the development of CKD in 230 patients, aged 34 (5–65) years, who had
undergone allogeneic HCT for haematological disease, using sibling or unrelated donors
and myeloablative or reduced conditioning regimens. Pre-HCT glomerular filtration rate
(GFR) was within normal limits (108±28 mL/min/1.73 m 2) in patients who did not develop …
Abstract
Chronic kidney disease (CKD) has been related to allogeneic haematopoietic cell transplantation (HCT) as a late effect caused by a variety of factors. We retrospectively evaluated the development of CKD in 230 patients, aged 34 (5–65) years, who had undergone allogeneic HCT for haematological disease, using sibling or unrelated donors and myeloablative or reduced conditioning regimens. Pre-HCT glomerular filtration rate (GFR) was within normal limits (108±28 mL/min/1.73 m 2) in patients who did not develop CKD and 95±24 mL/min/1.73 m 2 in those with CKD postHCT, while the GFR 12 months post transplant declined to 104±26 and 69±19 mL/min/1.73 m 2, respectively. CKD incidence was 20.4%, with a median time of development of 6 (3–18) months post transplant. On multivariate analysis, risk factors for CKD were the presence of chronic GVHD (cGVHD; P= 0.001), unrelated donor transplantation (P= 0.008), post-transplant event of acute kidney injury (AKI)(P= 0.002) and older age (P= 0.002). In long-term survivors stable significant predictors for CKD were older age at transplantation, cGVHD and AKI. CKD did not influence non-relapse mortality. In our study, cGVHD emerges as an important cause of kidney injury in HCT survivors, regardless of administration of nephrotoxic agents.
nature.com